Vaxart

Update in progress

VXRT (OTC Markets OTCQX)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Vaxart, Inc. is a clinical-stage biotechnology company developing oral recombinant protein vaccines using its vector-adjuvant-antigen platform. Its pipeline includes a bivalent norovirus oral tablet in Phase 2 for GI.1 and GII.4; a COVID-19 vaccine in Phase 2b for SARS-CoV-1, SARS-CoV-2, and MERS; a seasonal influenza vaccine in Phase 2 for H1N1; and a preclinical HPV therapeutic vaccine targeting HPV-16/18. It licenses Vapendavir from Altesa. HQ: South San Francisco.

Company score

Sentiment: 0.18; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.07; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.14; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.09; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.08; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.13; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive